Hillsdale Investment Management Inc. lifted its position in Eli Lilly And Co (NYSE:LLY) by 1,071.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,450 shares of the company’s stock after acquiring an additional 4,070 shares during the period. Hillsdale Investment Management Inc.’s holdings in Eli Lilly And Co were worth $494,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Meridian Wealth Management LLC purchased a new stake in Eli Lilly And Co in the first quarter valued at $38,000. Ellis Investment Partners LLC purchased a new stake in Eli Lilly And Co in the first quarter valued at $39,000. Manchester Financial Inc. purchased a new stake in Eli Lilly And Co in the second quarter valued at $40,000. Litman Gregory Asset Management LLC purchased a new stake in Eli Lilly And Co in the second quarter valued at $47,000. Finally, Personal Wealth Partners purchased a new stake in Eli Lilly And Co in the second quarter valued at $53,000. 78.92% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts have commented on the stock. Zacks Investment Research lowered shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday, May 21st. BMO Capital Markets upped their price target on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. Goldman Sachs Group assumed coverage on shares of Eli Lilly And Co in a report on Tuesday, May 28th. They issued a “buy” rating and a $135.00 price target on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $143.00 price target on shares of Eli Lilly And Co in a report on Tuesday, April 30th. Finally, Edward Jones raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price target on the stock in a report on Tuesday, April 23rd. Nine analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $123.49.
Shares of LLY stock traded down $0.56 during mid-day trading on Tuesday, hitting $111.97. 146,323 shares of the stock were exchanged, compared to its average volume of 4,170,914. The firm has a fifty day moving average of $110.62 and a 200 day moving average of $117.93. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 4.98. Eli Lilly And Co has a 52-week low of $103.65 and a 52-week high of $132.13. The company has a market cap of $106.70 billion, a PE ratio of 20.17, a price-to-earnings-growth ratio of 1.95 and a beta of 0.19.
Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The business had revenue of $5.64 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the company posted $1.48 EPS. The company’s revenue for the quarter was up .9% on a year-over-year basis. Equities analysts predict that Eli Lilly And Co will post 5.72 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a dividend yield of 2.30%. The ex-dividend date of this dividend is Wednesday, August 14th. Eli Lilly And Co’s payout ratio is currently 46.49%.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: What is Green Investing?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.